|Articles|July 16, 2014
Chiltern Acquires Ockham
Chiltern and Ockham announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.
Advertisement
Chiltern and Ockham, two full-service contract research organizations (CROs), announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.
The combined company will be called Chiltern. Ockham’s management team will join the management of the enlarged group. Chiltern’s CEO Jim Esinhart, PhD will be CEO of the Chiltern Group, with Ockham’s CEO, James V. Baker, becoming Chief Development Officer. Nick Thornton will remain as Chairman.
The merged entity combines service offerings in three areas: oncology; services and FSP/Sourcing
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Patient Centricity: What Rare Disease Research Gets Right
2
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
3
ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD
4
Why Payment Performance Has Become an Operational Brand for Sponsors: Q&A with Patrick Mizer, Ledger Run
5